Neoplasm, Residual: Clinical Trials

117 trials for Neoplasm, Residual, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

32 recruiting, 24 completed, 16 active not recruiting, 13 unknown. 117 Phase 2, 19 Phase 1, 10 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2117Recruiting 32, Completed 24, Active not recruiting 16, Unknown 13, Not yet recruiting 12, Terminated 10, Withdrawn 6, Enrolling by invitation 2, Suspended 2
Phase 119Recruiting 5, Active not recruiting 4, Terminated 4, Withdrawn 3, Not yet recruiting 1, Suspended 1, Unknown 1
Phase 310Completed 5, Unknown 2, Enrolling by invitation 1, Not yet recruiting 1, Recruiting 1

Follow Neoplasm, Residual: new trials by email Literature Review of Neoplasm, Residual trials Research Report on Neoplasm, Residual

Trials (filtered) newest first · largest first

All 117 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy
INCA33890 - CRC (Colorectal Cancer)
Phase 2RecruitingIncyte Corporation402026-12-142026-11-17
MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma
Low-Dose Radiation Therapy (LDRT), Standard Frontline Chemoimmunotherapy - Diffuse Large B-Cell Lymphoma
Phase 2Not yet recruitingUniversity of Nebraska502026-12-122026-11-06
A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant
Maintenance Therapy, No intervention - Myeloid Disorders, Myelodysplastic Syndromes
Phase 2Not yet recruitingMedical College of Wisconsin4502026-12-012026-10-13
Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients
Befotinib, Pemetrexed + Cisplatin /Carboplatin - Advanced Non-small Cell Lung Cancer (NSCLC), EGFR Exon 19 Deletion Mutation
Phase 2RecruitingGuangzhou University of Traditional Chinese Medicine1242026-11-302026-11-04
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803 - Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma
Phase 1 / Phase 2SuspendedNational Cancer Institute (NCI)302026-11-242026-11-19
MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC
PD-1 inhibitor, Carboplatin, Nab-paclitaxel - Non-Small Cell Lung Cancer (NSCLC)
Phase 2Not yet recruitingPeking University People's Hospital1002026-11-012026-10-21
Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Dexamethasone, Mezigdomide, Elranatamab - Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Phase 2Not yet recruitingPETHEMA Foundation602026-11-012026-10-28
CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
CM336 (BCMA/CD3 bispecific antibody), Daratumumab, Lenalidomide - Multiple Myeloma
Phase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China242026-10-152026-10-26
Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.
Belantamab Mafodotin, Pomalidomide, Dexamethasone - Relapsed / Refractory Multiple Myeloma
Phase 2Not yet recruitingPolish Myeloma Consortium2282026-10-012026-08-06
Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia
Nemtabrutinib, Venetoclax, Obinutuzumab - Chronic Lymphocytic Leukemia
Phase 2Not yet recruitingMedical College of Wisconsin302026-10-012026-07-08
SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response
SHR-A1811, Trastuzumab, Pertuzumab - HER2-positive Breast Cancer, Early Breast Cancer (EBC)
Phase 2Not yet recruitingFudan University3582026-10-012026-10-02
Perioperative Adebrelimab for Locally Advanced Cervical Cancer
Adebrelimab, Paclitaxel, Cisplatin - Locally Advanced Cervical Cancer
Phase 2Not yet recruitingAnhui Provincial Hospital352026-10-012026-09-10
ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer
PD-1 inhibitor, CTLA-4 inhibitor, ctDNA/MRD testing - Colon Cancer, Deficient Mismatch Repair
Phase 2RecruitingFudan University232026-09-142026-09-25
Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure
Lisaftoclax (APG-2575), homoharringtonine, Azacitidine (AZA) - Acute Myeloid Leukemia (AML)
Phase 2Enrolling by invitationGuangdong Second Provincial General Hospital732026-09-012026-09-10
Motixafortide for MRD Sensitization in AML
Motixafortide - Acute Myeloid Leukemia, Measurable Residual Disease
Phase 2RecruitingWashington University School of Medicine102026-07-232026-07-24
Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
Chidamide - Diffuse Large B-Cell Lymphoma
Phase 2RecruitingRong Tao692026-06-162026-06-18
VEN+IDAC vs IDAC in AML
Ventoclax, Cytarabine - AML (Acute Myelogenous Leukemia)
Phase 2 / Phase 3Enrolling by invitationGuangdong Second Provincial General Hospital2322026-04-012026-04-17
Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients
Allogenic expanded Natural Killer Cells (AlloNK1) - Nasopharyngeal Carcinoma (NPC), Minimal Residual Disease
Phase 1 / Phase 2Not yet recruitingSingapore General Hospital312026-04-012026-03-30
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
Ivonescimab, Docetaxel, Standard Treatment group - Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)
Phase 2RecruitingSecond Xiangya Hospital of Central South University702026-03-102026-03-09
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
Datopotamab deruxtecan, Circulating tumor DNA (ctDNA) testing - Breast Cancer, Residual Disease
Phase 2RecruitingUNC Lineberger Comprehensive Cancer Center782026-02-262026-11-13

Showing 20 of 117. Sign in to see all of them.

Narrower conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma (22)  ·  Leukemia, Myeloid, Acute (21)  ·  Multiple Myeloma (11)  ·  Breast Neoplasms (9)  ·  Burkitt Lymphoma (9)  ·  Recurrence (9)  ·  Myelodysplastic Syndromes (7)  ·  Carcinoma, Non-Small-Cell Lung (6)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (6)  ·  Leukemia (5)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (5)  ·  Triple Negative Breast Neoplasms (5)  ·  Colonic Neoplasms (4)  ·  Colorectal Neoplasms (4)

Broader conditions

Neoplasms (117)  ·  Neoplastic Processes (117)  ·  Pathologic Processes (117)  ·  Pathological Conditions, Signs and Symptoms (117)  ·  Neoplasms by Histologic Type (80)  ·  Hemic and Lymphatic Diseases (72)  ·  Hematologic Diseases (62)  ·  Immune System Diseases (51)  ·  Immunoproliferative Disorders (50)  ·  Lymphoproliferative Disorders (49)  ·  Leukemia (47)  ·  Lymphatic Diseases (40)  ·  Neoplasms by Site (34)  ·  Leukemia, Lymphoid (28)  ·  Leukemia, Myeloid (26)

Interventions

blinatumomab (12)  ·  Cyclophosphamide (11)  ·  Azacitidine (9)  ·  Dexamethasone (8)  ·  Lenalidomide (8)  ·  venetoclax (8)  ·  Cytarabine (7)  ·  Rituximab (6)  ·  Carboplatin (5)  ·  daratumumab (5)  ·  fludarabine (5)  ·  fludarabine phosphate (4)  ·  pembrolizumab (4)  ·  Busulfan (3)  ·  Immune Checkpoint Inhibitors (3)

Sponsors

Nanfang Hospital, Southern Medical University (7)  ·  M.D. Anderson Cancer Center (6)  ·  National Cancer Institute (NCI) (4)  ·  Novartis Pharmaceuticals (4)  ·  Goethe University (3)  ·  Institute of Hematology & Blood Diseases Hospital, China (3)  ·  Medical College of Wisconsin (3)  ·  Peking University People's Hospital (3)  ·  Amgen (2)  ·  Amgen Research (Munich) GmbH (2)  ·  Beijing 302 Hospital (2)  ·  Fudan University (2)  ·  Gruppo Italiano Malattie EMatologiche dell'Adulto (2)  ·  Guangdong Second Provincial General Hospital (2)  ·  Masonic Cancer Center, University of Minnesota (2)

Countries

United States (47)  ·  China (28)  ·  Germany (13)  ·  Italy (10)  ·  Spain (10)  ·  France (7)  ·  Canada (5)  ·  Belgium (4)  ·  Netherlands (4)  ·  Poland (4)  ·  United Kingdom (4)  ·  Australia (3)  ·  Austria (3)  ·  Mexico (3)  ·  Norway (3)

Top investigators

Qifa Liu (4)  ·  David S Schrump, M.D. (2)  ·  Nicola Goekbuget, MD (2)  ·  Robert J Kreitman, M.D. (2)  ·  Aaron Goldberg, MD, PhD (1)  ·  Albert Oriol, PhD (1)  ·  Alessandro Rambaldi (1)  ·  Alfonso Quintas-Cardama, MD (1)  ·  Amanda Olson (1)  ·  Amer Zeidan (1)  ·  Andrzej Jakubowiak (1)

Results publications

PMID 19141862, PMID 26308596, PMID 27209293, PMID 29358182, PMID 32619115, PMID 41671463, PMID 14710949, PMID 16195338, PMID 20087581, PMID 20388201, PMID 20606084, PMID 21719599, PMID 22058217, PMID 22442346, PMID 22592608, PMID 22851565, PMID 2350571, PMID 24128322, PMID 25192414, PMID 25749825, PMID 25966987, PMID 25999452, PMID 26778538, PMID 27216216, PMID 27511158, PMID 27531679, PMID 27557302, PMID 27618682, PMID 27705267, PMID 27717585, PMID 27859027, PMID 27896689, PMID 27913532, PMID 28054442, PMID 28379796, PMID 28494052, PMID 28835441, PMID 29127588, PMID 29305553, PMID 29388200, PMID 29884853, PMID 30037340, PMID 30254079, PMID 30255106, PMID 30498492, PMID 30702598, PMID 30831554, PMID 31324600, PMID 31435023, PMID 31452197

NIH funding

2023 (4), 2017 (2), P30CA015704 (2), 2015 (1), 2018 (1), 2019 (1), 2025 (1), K12HL087165 (1), P30CA014599 (1), P30CA016672 (1), R01CA290013 (1), U10CA180820 (1)